Sandbox Rim: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In AF patients, stroke risk must be assessed using the CHA2-DS2-VASc score, and bleeding risk assessed using the HAS-BLED score.2 Risk stratification is a dynamic process, and must be performed at regular intervals (i.e. on a yearly basis). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: c]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Where adjusted dose VKA is used, good quality anticoagulation control is recommended, with a TTR >70%. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|} | |} | ||
| Line 11: | Line 11: | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ | | colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' When VKA is given in combination with clopidogrel and/or low-dose aspirin, the dose intensity of VKA should be carefully regulated, with a target INR range of 2.0–2.5. ''([[JNC guidelines classification scheme#Evidence Quality Rating|Level of Evidence: Grade C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' In a patient with AF and stable vascular disease (arbitrarily defined as being free from any acute ischaemic event or repeat revascularization for >1 year) the patient should be managed with OAC alone (i.e. whether NOAC or a VKA). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade B]])''<nowiki>"</nowiki> | ||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' Radial access should be considered as the default for coronary angiography/intervention to minimize the risk of access related bleeding depending on operator expertise and preference. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Where aNOACis used in combination with clopidogrel and/or low-dose aspirin, the lower tested dose for stroke prevention in AF (that is, dabigatran 110 mg b.i.d., rivaroxaban 15 mg o.d. or apixaban 2.5 mg b.i.d.) may be considered (Prescribing information for edoxaban awaited.). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Newgeneration DES may be preferred over BMS in patients at low risk of bleeding (i.e. HAS-BLED 0–2). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki> | |||
|- | |- | ||
|} | |} | ||
Revision as of 18:17, 4 September 2014
| Class I |
| "1. In AF patients, stroke risk must be assessed using the CHA2-DS2-VASc score, and bleeding risk assessed using the HAS-BLED score.2 Risk stratification is a dynamic process, and must be performed at regular intervals (i.e. on a yearly basis). (Level of Evidence: c)" |
| "2. Where adjusted dose VKA is used, good quality anticoagulation control is recommended, with a TTR >70%. (Level of Evidence: A)" |
| Class IIa |
| "1. When VKA is given in combination with clopidogrel and/or low-dose aspirin, the dose intensity of VKA should be carefully regulated, with a target INR range of 2.0–2.5. (Level of Evidence: Grade C)" |
| "2. In a patient with AF and stable vascular disease (arbitrarily defined as being free from any acute ischaemic event or repeat revascularization for >1 year) the patient should be managed with OAC alone (i.e. whether NOAC or a VKA). (Level of Evidence: Grade B)" |
| "3. Radial access should be considered as the default for coronary angiography/intervention to minimize the risk of access related bleeding depending on operator expertise and preference. (Level of Evidence: Grade C)" |
| Class IIb |
| "1. Where aNOACis used in combination with clopidogrel and/or low-dose aspirin, the lower tested dose for stroke prevention in AF (that is, dabigatran 110 mg b.i.d., rivaroxaban 15 mg o.d. or apixaban 2.5 mg b.i.d.) may be considered (Prescribing information for edoxaban awaited.). (Level of Evidence: Grade C)" |
| "2. Newgeneration DES may be preferred over BMS in patients at low risk of bleeding (i.e. HAS-BLED 0–2). (Level of Evidence: Grade C)" |